Oxford Asset Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Oxford Asset Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-20,475	Closed	-$471K	–	696
2025 Q4	$471K	Buy	+20,475	New	+$673K	0.17%	203
2025 Q2	–	Sell	-8,421	Closed	-$305K	–	725
2025 Q1	$305K	Buy	+8,421	New	+$350K	0.14%	252
2019 Q2	–	Sell	-3,101	Closed	-$215K	–	1915
2019 Q1	$215K	Buy	+3,101	New	+$177K	﹤0.01%	1493
2018 Q3	–	Sell	-8,152	Closed	-$621K	–	1886
2018 Q2	$621K	Buy	8,152 +4,143	+103%	+$268K	0.01%	1257
2018 Q1	$204K	Buy	+4,009	New	+$202K	﹤0.01%	1484
2016 Q1	–	Sell	-28,031	Closed	-$3.17M	–	878
2015 Q4	$3.17M	Buy	+28,031	New	+$2.8M	0.07%	293

Other funds holding RARE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Oxford Asset Management's RARE Position: Q1 2026 in Review

Oxford Asset Management sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2026, closing a stake of 20,475 shares — an estimated $471K sold.

Oxford Asset Management first reported a position in RARE in Q4 2015 and held it in 6 quarters. The position peaked at $3.17M in Q4 2015. 298 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

Oxford Asset Management reported no remaining Ultragenyx Pharmaceutical position as of Q1 2026 after selling out during the quarter.
Oxford Asset Management sold 20,475 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $471K.
Oxford Asset Management first reported a position in Ultragenyx Pharmaceutical in Q4 2015 and held it in 6 quarters.
Oxford Asset Management's Ultragenyx Pharmaceutical position peaked at $3.17M in Q4 2015.
298 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Oxford Asset Management's 13F filing for Q1 2026, filed 15 May 2026.